LEADER 00000cam a2200349 a 4500 
001    on1109843153 
006    m     o  d         
007    cr cnu---unuuu 
008    190722s2020    enka   gob    001 0 eng d 
020    9780128197479 (electronic bk.) 
020    0128197471 (electronic bk.) 
020    9780128195734 
020    0128195738 
035    (OCoLC)1109843153 
040    N$T|beng|cN$T|dN$T|dOCLCF|dOPELS|dVRC|dLVT|dAS 
041 0  eng 
050  4 RM275 
082 04 616.079|223 
100 1  Balkhi, Mumtaz Yaseen,|eauthor 
245 10 Basics of chimeric antigen receptor (CAR) immunotherapy
       |h[electronic resource] /|cMumtaz Yaseen Balkhi 
260    [London] :|bAcademic Press,|c2020 
300    1 online resource 
504    Includes bibliographical references and index 
520    Basics of Chimeric Antigen Receptor (CAR) Immunotherapy 
       presents the latest on how T cell adoptive immunotherapy 
       has progressed in its ultimate goal of curing metastatic 
       malignant cancers. Recent clinical data obtained with 
       checkpoint receptor blockade inhibitors and chimeric 
       antigen receptor (CAR) therapy has been especially 
       promising, thus generating renewed hope that we may be on 
       the verge of finally curing cancer. Over the years, huge 
       progress has been made in controlling several stage IV 
       metastasized cancers through the clinical application of 
       checkpoint receptor inhibitory drugs and CAR-Therapy that 
       has seen unprecedented interest in the immunotherapy field
650  0 Immunotherapy 
650  0 Cancer|xTreatment 
650  0 Genetic engineering 
650  7 Cancer|xTreatment.|2fast|0(OCoLC)fst00845538 
650  7 Genetic engineering.|2fast|0(OCoLC)fst00940027 
650  7 Immunotherapy.|2fast|0(OCoLC)fst00968044 
655  4 Electronic books 
856 40 |uhttps://www.sciencedirect.com/science/book/9780128195734
       |zeBook(ScienceDirect)